News & Media

Recent updates from Arcutis.

August 10, 2023

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 8, 2023

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

August 4, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2023

Arcutis to Report Second Quarter Financial Results

July 17, 2023

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

July 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2023

Arcutis to Present at Upcoming Investor Conference

June 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2023

Arcutis Announces Leadership Transition

May 9, 2023

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

May 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2023

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download